Jazz Pharmaceuticals Announces Successful Completion of Term Loan Repricing and Irrevocable Election of Settlement Method for the 2.000% Exchangeable Senior Notes due 2026

July 23, 2024

https://www.prnewswire.com/news-releases/jazz-pharmaceuticals-announces-successful-completion-of-term-loan-repricing-and-irrevocable-election-of-settlement-method-for-the-2-000-exchangeable-senior-notes-due-2026–302201827.html

DUBLIN, July 22, 2024 /PRNewswire/ — Jazz Pharmaceuticals plc (Nasdaq: JAZZ) (“Jazz Pharmaceuticals”) today announced that it has completed a repricing of the approximately $2.7 billion outstanding balance of its U.S. dollar term loans under its credit facility. The applicable margin above Term SOFR will be reduced by 75 basis points (from 300 basis points to 225 basis points) and the credit spread adjustment will be removed, resulting in anticipated interest savings of approximately $23 million on an annualized basis. All other terms are substantially unchanged.

Read more at prnewswire.com

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.